MarketsSingle-source
2.0
PDS Biotechnology Corp Announces Executive Departure and Restructuring Costs
SEC EDGAR 8-K FilingsLO·US·3 days ago
BioXcel Therapeutics has filed an 8-K disclosing a bankruptcy or receivership event alongside a new material definitive agreement. The filing indicates a significant shift in the company's financial status, though specific terms of the restructuring or agreement remain to be detailed in subsequent filings.